ResultsIQ

ResultsIQ › Latest results › Advanced Enzyme Technologies Limited

Advanced Enzyme Technologies Limited Q4 FY26 results press release summary

NSE: ADVENZYMES · BSE: 540025

Results press release of 9 May 2026, summarised by AI from the filing.

Revenue ₹ 2,034 million (+22% y-o-y), EBITDA ₹ 632 million (+39%), PAT ₹ 453 million (+69%).

Key takeaways

  1. Q4 FY26 results Revenue ₹ 2,034 million (+22% y-o-y), EBITDA ₹ 632 million (+39%), PAT ₹ 453 million (+69%).
  2. Domestic sales Domestic sales rose 51% y-o-y to ₹ 1,061 million in Q4 FY26, forming 52% of revenue vs 42% in Q4 FY25.
  3. Human Nutrition Segment revenue grew 24% y-o-y to ₹ 1,281 million, driven by Pharma/API and Bio-catalysis; expected to be a key growth driver.

Original filing on BSE

Advanced Enzyme Technologies Limited Q1 FY27 results

As filed: Revenue ₹190 cr (+2% year on year), EBITDA ₹51.0 cr (−11% year on year), PAT ₹38.6 cr (−4% year on year), EBITDA margin 26.9% (−379 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹116 cr (+34% year on year), EBITDA ₹26.9 cr (+92% year on year), PAT ₹22.3 cr (+103% year on year), EBITDA margin 23.1% (+698 bps). Score 84 of 100, Above trend. Revenue and profit growth were above the company's own trend; EBITDA growth was well above it. EBITDA margin rose 698 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Profit rose ₹11.3 cr on a year ago, more than the ₹8.0 cr it added the year before. Share price after the results: +4.1% in 30 days (Nifty 500: −4.1%).
  • Q3 FY26: Revenue ₹172 cr (+2% year on year), EBITDA ₹49.4 cr (−10% year on year), PAT ₹43.2 cr (−11% year on year), EBITDA margin 28.7% (−384 bps). Score 25 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA and profit before exceptional items growth were well below it. EBITDA margin fell 384 bps year on year. Revenue fell 7% from last quarter. Share price after the results: +8.6% in 30 days (Nifty 500: −1.1%).
  • Q2 FY26: Revenue ₹185 cr (+27% year on year), EBITDA ₹61.0 cr (+45% year on year), PAT ₹45.0 cr (+36% year on year), EBITDA margin 33.0% (+421 bps). Score 81 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin rose 421 bps year on year. Share price after the results: +0.3% in 30 days (Nifty 500: +0.2%).
  • Q1 FY26: Revenue ₹186 cr (+20% year on year), EBITDA ₹57.0 cr (+10% year on year), PAT ₹40.0 cr (+14% year on year), EBITDA margin 30.7% (−290 bps). Score 58 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were in line with it. EBITDA margin fell 290 bps year on year. Share price after the results: −6.0% in 30 days (Nifty 500: +0.2%).
  • Q4 FY25: Revenue ₹87.0 cr (−5% year on year), EBITDA ₹14.0 cr (−52% year on year), PAT ₹11.0 cr (+267% year on year), EBITDA margin 16.1% (−1,000 bps). Score 36 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA growth was well below it; profit growth was well above it. EBITDA margin fell 1000 bps year on year. Other income 31% of PBT. Revenue fell 14% from last quarter. Share price after the results: +9.6% in 30 days (Nifty 500: +2.4%).
  • Q3 FY25: Revenue ₹169 cr (+5% year on year), EBITDA ₹55.0 cr (0% year on year), PAT ₹39.0 cr (−9% year on year), EBITDA margin 32.5% (−162 bps). Score 37 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were below it. EBITDA margin fell 162 bps year on year.
  • Q2 FY25: Revenue ₹146 cr (−8% year on year), EBITDA ₹42.0 cr (−19% year on year), PAT ₹33.0 cr (−6% year on year), EBITDA margin 28.8% (−414 bps). Score 16 of 100, Below trend. EBITDA margin fell 414 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 6% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

Advanced Enzyme Technologies Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.